The cost-efficacy of combined anti-inflammatory therapy in the treatment of children in severe persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 134s Year: 2003
Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017
Long-term efficacy of QMF149 in persistent asthma Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
Efficacy of ruzam in the treatment of patients with mild-to-moderate asthma Source: Eur Respir J 2004; 24: Suppl. 48, 131s Year: 2004
The efficacy of omalizumab in severe in asthma after treatment withdrawal Source: Annual Congress 2009 - Towards improving asthma control Year: 2009
The oral corticosteroid sparing effect of omalizumab in paediatric patients with severe chronic asthma Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010
‘Real-life‘ persistence beyond the first year of omalizumab treatment in patients with severe allergic asthma: The R-Pixel study Source: Annual Congress 2011 - Asthma management and response Year: 2011
Predictors of effectiveness of omalizumab treatment in patients with severe asthma recruited in a real-life setting Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015
The 1-year cost-effectiveness of roflumilast for the treatment of severe to very severe COPD patients Source: Eur Respir J 2007; 30: Suppl. 51, 194s Year: 2007
Analysis of two-year treatment with omalizumab patients with severe asthma in real clinical practice Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019
The effect of long-term treatment with erdosteine on moderate or severe COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 292s Year: 2005
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005
Clinical benefits and safety of long term treatment with montelukast (M) in patients with mild-to-moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001
Treatment of moderate to severe asthma with ciclesonide: a long-term investigation over 52 weeks Source: Eur Respir J 2002; 20: Suppl. 38, 406s Year: 2002
Patients with moderate asthma symptoms may benefit from short-term inhaled corticosteroid monotherapy Source: Eur Respir J 2007; 30: Suppl. 51, 615s Year: 2007
Comparison of the efficacy of cicleosonide with budesonide in mild to moderate asthma patients after step-down therapy Source: Annual Congress 2011 - Asthma management and response Year: 2011
Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015
A longitudinal follow-up of severe asthma patients receiving reslizumab Source: International Congress 2017 – Asthma management Year: 2017
Physicians judge add-on omalizumab therapy as an effective treatment for patients with severe persistent allergic asthma: a pooled analysis Source: Eur Respir J 2005; 26: Suppl. 49, 49s Year: 2005
The oral corticosteroid sparing effect of omalizumab in patients with severe chronic asthma: Is there a difference when you become 12 years old? Source: Annual Congress 2011 - Treating childhood asthma Year: 2011